Vectorite Biomedical

Executive Summary

Vectorite Biomedical is a Taiwan-based biotech company focused on developing and manufacturing autologous immune cell therapies, particularly dendritic cell (DC) and natural killer (NK) cell platforms, along with extracellular vesicle (exosome) products. Its proprietary artificial antigen technology and NK cell expansion method enable high-purity, clinically grade cell therapies without the need for surgical tumor biopsies. The company's therapeutic focus spans oncology, immunology, and regenerative medicine, positioning it as a versatile player in the cell therapy space. Founded in 2020 and currently in Phase I development, Vectorite Biomedical is advancing its leading candidates toward clinical proof-of-concept. The company's unique approach to antigen presentation and cell expansion could address key limitations in adoptive cell therapy, potentially improving patient outcomes. Upcoming catalysts include early clinical data readouts, potential strategic partnerships, and regulatory progress in Taiwan or the US. With a strong patent portfolio and a differentiated technology platform, Vectorite represents an emerging opportunity in the cell therapy landscape.

Upcoming Catalysts (preview)

• Q1 2027Initial Phase I clinical data for lead NK cell therapy candidate75% success
• Q4 2026Strategic partnership or licensing deal for DC/exosome platform40% success
• Q2 2026Regulatory submission for clinical trial application (CTA) in the US60% success